Argenica Therapeutics Receives approval to commence final ARG-007 dosing
- Argenica Therapeutics (AGN) receives approval to progress to the fourth and final cohort dosing of ARG-007 in its phase one trial
- Following an extensive review of data from the third cohort of participants, the company received notice from the safety review committee (SRC) that no clinically relevant abnormal results due to administration of the drug were recorded
- The company has been working to develop novel therapeutics to reduce brain tissue death after strokes and other types of brain injury
- AGN says it will provide a final update on the phase one clinical trial at the completion of the final cohort safety data review in late December
- ArgenicaTherapeutics is down 4.04 per cent, trading at 47.5 cents just before market close
